Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
|Druh||Článek v odborném periodiku|
|Časopis / Zdroj||Haematologica|
|Fakulta / Pracoviště MU|
|Obor||Onkologie a hematologie|
|Klíčová slova||Nilotinib; insulin resistance|
|Popis||For the first time we have clarified the mechanism of impaired glucose metabolism in CML patients treated with nilotinib, which occurs via rapidly developed tissue insulin resistance and compensatory hyperinsulinemia. It also at least partially explains the fast development of dyslipidemia and probably also PAO in these CML patients. However, further studies that include a larger patient cohort, as well as in vitro tests to confirm postreceptor insulin resistance, are needed, and these are already ongoing in our study group.|